Condition
Perennial Allergic Rhinoconjunctivitis
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT00574704Phase 2CompletedPrimary
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
NCT00574223Phase 2CompletedPrimary
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
NCT00652223Phase 1CompletedPrimary
Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy
Showing all 3 trials